Global Market Direct’s pharmaceuticals report, “Okairos AG - Product Pipeline Review - 2013” provides data on the Okairos AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Okairos AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Okairos AG and industry-specific third party sources, put together by Global Markets Direct’s team.
- Okairos AG - Brief Okairos AG overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Okairos AG human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Okairos AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Okairos AG’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Okairos AG’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Okairos AG in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Okairos AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Okairos AG. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Okairos AG and identify potential opportunities in those areas.
Table Of Contents
Okairos AG - Product Pipeline Review - 2013 Table of Contents 2 List of Tables 4 List of Figures 4 Okairos AG Snapshot 5 Okairos AG Overview 5 Key Information 5 Key Facts 5 Okairos AG - Research and Development Overview 6 Key Therapeutic Areas 6 Okairos AG - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Okairos AG - Pipeline Products Glance 10 Okairos AG Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Phase I Products/Combination Treatment Modalities 11 Okairos AG - Early Stage Pipeline Products 12 Pre-Clinical Products/Combination Treatment Modalities 12 Okairos AG - Drug Profiles 13 Cancer Vaccine 13 Product Description 13 Mechanism of Action 13 RandD Progress 13 Ebola And Marburg Vaccine Programme 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 HIV Vaccine Program 15 Product Description 15 Mechanism of Action 15 RandD Progress 15 Malaria Vaccine Programme 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 ProCvax 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 Respiratory Syncytial Virus Vaccine Programme 18 Product Description 18 Mechanism of Action 18 RandD Progress 18 TerCvax 19 Product Description 19 Mechanism of Action 19 RandD Progress 19 Tuberculosis Vaccine Program 21 Product Description 21 Mechanism of Action 21 RandD Progress 21 Universal Influenza Vaccine Program 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 Okairos AG - Pipeline Analysis 23 Okairos AG - Pipeline Products by Therapeutic Class 23 Okairos AG - Pipeline Products by Route of Administration 25 Okairos AG - Recent Pipeline Updates 26 Okairos AG - Dormant Projects 28 Okairos AG - Locations And Subsidiaries 29 Head Office 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables
Okairos AG, Key Information 5 Okairos AG, Key Facts 5 Okairos AG - Pipeline by Indication, 2013 7 Okairos AG - Pipeline by Stage of Development, 2013 8 Okairos AG - Monotherapy Products in Pipeline, 2013 9 Okairos AG - Phase II, 2013 10 Okairos AG - Phase I, 2013 11 Okairos AG - Pre-Clinical, 2013 12 Okairos AG - Pipeline By Therapeutic Class, 2013 24 Okairos AG - Pipeline By Route of Administration, 2013 25 Okairos AG - Recent Pipeline Updates, 2013 26 Okairos AG - Dormant Developmental Projects,2013 28
List of Figures
Okairos AG - Pipeline by Indication, 2013 7 Okairos AG - Pipeline by Stage of Development, 2013 8 Okairos AG - Monotherapy Products in Pipeline, 2013 9 Okairos AG - Pipeline By Therapeutic Class, 2013 23 Okairos AG - Pipeline By Route of Administration, 2013 25